Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06198452

Vision Improvement for Patients With Age-Related Macular Degeneration

This study is being conducted to assess the safety and efficacy of the VIS, LLC (VIS) Opti-K Low Vision Aid Device and treatment to provide vision improvement to patients with age-related macular degeneration.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

50 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

This study is being conducted to assess the safety and efficacy of the VIS, LLC (VIS) Opti-K Low Vision Aid Device and treatment to provide vision improvement to patients with age-related macular degeneration.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects who meet all of the following criteria are candidates for this study:

  • Male or Female
  • Any race
  • Patient is at least 50 years old.
  • Patient has diagnosed end stage dry or wet age-related macular degeneration in one or both eyes, as verified by a complete ocular examination.
  • Patient is pseudophakic or is phakic with no clinically significant cataract in eye(s) to be treated.
  • Patient has manifest refraction, spherical equivalent (MRSE) between -1.50 D to 1.50 D in eye(s) to be treated.
  • Patient has moderate to severe vision impairment due to age-related macular degeneration with best spectacle-corrected distance visual acuity (CDVA) of 20/80 or worse (decimal less than or equal to 0.25; logMAR ≥ 0.60).in the better eye.
  • Patient has CDVA of 20/400 or better (decimal greater than or equal to 0.05; logMAR ≤ 1.30) in the worse eye.
  • Patient is not a contact lens (CL) wearer.
  • Patient is willing and able to comply with all examinations.
  • Patient must be competent to sign an informed consent form before study entry.

Exclusion criteria

Subjects who meet any of the following criteria are to be excluded from this study:

  • Corneal disease or corneal disorder in either eye.
  • Pathological retinal morphology in either eye that completely affects the entire 10° (3 mm diameter) of the retina centered on the foveola.
  • Gonzalez-Markowitz chart Potential Visual Acuity (PVA) in the eye to be treated that is not improved by at least four lines compared to CDVA;
  • Increased IOP (above 20 mm Hg), glaucoma or history of glaucoma;
  • Previous corneal surgery in the eye to be treated; and
  • Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable as a candidate for study participation or that may confound the outcome of the study.

Treatment and study plan

Vision Improvement

Procedure

Laser Vision Improvement for Patients with Age-Related Macular Degeneration

Primary outcomes

  1. Visual Acuity

    Time frame: 1 year

    Standard measurements of visual acuity before and after treatment

Study contacts

Contact information is provided by the study sponsor or research team.

Michael Berry, PhD

CONTACT

[email protected]

8318691384

Sponsors and collaborators

Lead sponsor

VIS, Inc.

Industry

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Jan 10, 2024
Registry last updated
Sep 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.